These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 29477393)

  • 41. Value Frameworks in Oncology: Comparative Analysis and Implications to the Pharmaceutical Industry.
    Slomiany M; Madhavan P; Kuehn M; Richardson S
    Am Health Drug Benefits; 2017 Jul; 10(5):253-260. PubMed ID: 28975009
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of health economics in the evaluation of surgery and operative technologies.
    Taylor M
    Surgery; 2017 Feb; 161(2):300-304. PubMed ID: 28096035
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Review: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Goettsch WG; Enzing J
    Value Health; 2014; 17(1):1-2. PubMed ID: 24438710
    [No Abstract]   [Full Text] [Related]  

  • 45. Defining the Value of Health Technologies in Latin America: Developments in Value Frameworks to Inform the Allocation of Healthcare Resources.
    Pichon-Riviere A; Garcia-Marti S; Oortwijn W; Augustovski F; Sampietro-Colom L
    Int J Technol Assess Health Care; 2019 Jan; 35(1):64-68. PubMed ID: 30938278
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making: an interview with Marc Berger.
    Berger ML
    J Comp Eff Res; 2018 Jan; 7(1):11-13. PubMed ID: 29052427
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force.
    Crown W; Buyukkaramikli N; Sir MY; Thokala P; Morton A; Marshall DA; Tosh JC; Ijzerman MJ; Padula WV; Pasupathy KS
    Value Health; 2018 Sep; 21(9):1019-1028. PubMed ID: 30224103
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Budget impact analysis.
    Leelahavarong P
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Three Sets of Case Studies Suggest Logic and Consistency Challenges with Value Frameworks.
    Cohen JT; Anderson JE; Neumann PJ
    Value Health; 2017 Feb; 20(2):193-199. PubMed ID: 28237194
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Value-based medicine in oncology: the importance of perspective in the emerging value frameworks.
    Campolina AG
    Clinics (Sao Paulo); 2018 Dec; 73(suppl 1):e470s. PubMed ID: 30540119
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Toward a Hedonic Value Framework in Health Care.
    Basu A; Sullivan SD
    Value Health; 2017 Feb; 20(2):261-265. PubMed ID: 28237206
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Decision-making frameworks and considerations for informing coverage decisions for healthcare interventions: a critical interpretive synthesis.
    Morgan RL; Kelley L; Guyatt GH; Johnson A; Lavis JN
    J Clin Epidemiol; 2018 Feb; 94():143-150. PubMed ID: 28988959
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Methods for determining cost-benefit ratios for pharmaceuticals in Germany.
    von der Schulenburg J; Vauth C; Mittendorf T; Greiner W
    Eur J Health Econ; 2007 Sep; 8 Suppl 1():S5-31. PubMed ID: 17582539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. DEVELOPMENTS IN VALUE FRAMEWORKS TO INFORM THE ALLOCATION OF HEALTHCARE RESOURCES.
    Oortwijn W; Sampietro-Colom L; Habens F
    Int J Technol Assess Health Care; 2017 Jan; 33(2):323-329. PubMed ID: 28578735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. American Society of Clinical Oncology guidance statement: the cost of cancer care.
    Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
    J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare.
    Jönsson B; Hampson G; Michaels J; Towse A; von der Schulenburg JG; Wong O
    Eur J Health Econ; 2019 Apr; 20(3):427-438. PubMed ID: 30229376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
    Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
    Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of costs for health economic evaluation.
    Riewpaiboon A
    J Med Assoc Thai; 2014 May; 97 Suppl 5():S17-26. PubMed ID: 24964695
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.